AGIO - アギオス・ファ―マシュ―ティカルズ (Agios Pharmaceuticals Inc.) アギオス・ファ―マシュ―ティカルズ

 AGIOのチャート


 AGIOの企業情報

symbol AGIO
会社名 Agios Pharmaceuticals Inc (アギオス・ファ―マシュ―ティカルズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 アジオス・ファーマスーティカルズ(Agios Pharmaceuticals Inc.)はバイオ医薬品会社。同社は根本的に癌と先天性代謝異常(IEM)の治療法を変えるために代謝に対する深い理解と代謝酵素を阻害・活性化できる薬剤を開発する能力を結合して応用しようとする。同社はすでに癌と先天性代謝異常に対して新薬開発の目標を明確・有効にした。同社の2つの進んだ癌プログラムは「IDH1」と「IDH2」と呼ばれるイソクエン酸脱水素酵素1と2の変異を標的とする。同社の薬剤候補は他の細胞に見られるIDH1とIDH2の正常形態に対し、癌に見られるIDH1とIDH2の変異形態を特定する。   アギオス・ファ―マシュ―ティカルズは、がん代謝と先天性代謝異常の分野に特化した米国のバイオ医薬品企業。主製品候補は、変異型イソクエン酸脱水素酵素2「AG-221」及びイソクエン酸デヒドロゲナ―ゼ1「AG-120」。急性骨髄性白血病などの突然変異IDH2を保有する癌または、突然変異IDH1を保有する癌患者用の強力な阻害剤。   Agios Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the discovery and development of novel investigational medicines to treat cancer and rare genetic diseases. It focuses on diseases that are directly caused by changes in genes or chromosomes, often passed from one generation to the next. The company was founded by Lewis Clayton Cantley, Tak W. Mak, Craig B. Thompson and Shin-Shan Michael Su on August 7, 2007 and is headquartered in Cambridge, MA.
本社所在地 88 Sidney Street Cambridge MA 02139 USA
代表者氏名 David P. Schenkein David P. Schenkein
代表者役職名 President Chief Executive Officer Director 社長兼最高経営責任者(CEO)
電話番号 +1 617-649-8600
設立年月日 39295
市場名 NASDAQ National Market System
ipoyear 2013年
従業員数 382人
url www.agios.com
nasdaq_url https://www.nasdaq.com/symbol/agio
adr_tso
EBITDA EBITDA(百万ドル) -329.37600
終値(lastsale) 68.07
時価総額(marketcap) 3947554648.32
時価総額 時価総額(百万ドル) 3819.391
売上高 売上高(百万ドル) 70.33300
企業価値(EV) 企業価値(EV)(百万ドル) 3102.486
当期純利益 当期純利益(百万ドル) -324.99200
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Agios Pharmaceuticals Inc revenues increased from $21.9M to $49.2M. Net loss increased 7% to $159.6M. Revenues reflect Collaboration revenue - related party increase of 54% to $33.7M. Higher net loss reflects Research and development increase of 15% to $146.6M (expense) General and administrative increase of 66% to $38.5M (expense).

 AGIOのテクニカル分析


 AGIOのニュース

   Agios' IND for PKR Activator AG-946 Gets FDA Clearance  2020/03/24 12:08:00 Zacks Investment Research
The FDA passes Agios' (AGIO) investigational new drug application for its next-generation PKR activator, AG-946. The company plans to begin a phase I study on the same in mid-2020.
   The Daily Biotech Pulse: Pfizer's Eczema Drug Aces Latestage Study, Orphan Drug Designation For Dicerna, Dyadic's COVID-19 Connection  2020/03/19 11:37:15 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 18) Biomerica, Inc. (NASDAQ: BMRA )( announced commencement of international shipment of rapid COVID-19 test) BioNTech SE – ADR (NASDAQ: BNTX ) Imara Inc (NASDAQ: IMRA ) Down In The Dumps (Biotech Stocks Hitting 52-week lows on March 18) 89bio Inc (NASDAQ: ETNB ) AC Immune SA (NASDAQ: ACIU ) Acasti Pharma Inc (NASDAQ: ACST ) Accelerate Diagnostics Inc (NASDAQ: AXDX ) Aclaris Therapeutics Inc (NASDAQ: ACRS ) Adamas Pharmaceuticals Inc (NASDAQ: ADMS ) Adamis Pharmaceuticals Corp (NASDAQ: ADM ) Adial Pharmaceuticals Inc (NASDAQ: ADIL ) ADMA Biologics Inc (NASDAQ: ADMA ) Aerie Pharmaceuticals Inc (NASDAQ: AERI ) Aerpio Pharmaceuticals Inc (NASDAQ: ARPO ) AEterna Zentaris Inc. (NASDAQ: AEZS ) Agenus Inc (NASDAQ: AGEN ) Agios Pharmaceuticals Inc (NASDAQ: AGIO ) Aikido Pharma Inc (NASDAQ: AIKI ) Akorn, Inc. (NASDAQ: AKRX ) Alkermes Plc (NASDAQ: ALKS ) Allogene Therapeutics Inc (NASDAQ: ALLO ) Alterity Therapeutics Ltd (NASDAQ: ATHE ) AMAG Pharmaceuticals, Inc.
   Why Is Agios Pharmaceuticals (AGIO) Down 28.7% Since Last Earnings Report?  2020/03/14 15:30:46 Zacks Investment Research
Agios Pharmaceuticals (AGIO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
   Agios Pharmaceuticals (AGIO) Expected to Beat Earnings Estimates: Should You Buy?  2020/02/06 17:31:16 Zacks Investment Research
Agios Pharmaceuticals (AGIO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
   Analysts: 3 Healthcare Stocks That Could Gain 35% — Or More  2020/01/17 17:19:20 Nasdaq
Returns, that’s the name of the investing game. At the end of the day, investors are after the names that can help them generate a profit in the stock market. It’s as simple as that. The hard part, though, is determining which investment opportunities have the best chance of outperforming the market in the years to come. As not all stocks are created equal, Wall Street pros suggest doing some due diligence. This includes a close reading of what the analyst community has to say about the long-term growth prospects of a potential portfolio addition. Bearing this in mind, we applied this strategy to our own search for compelling investments in the healthcare space. With TipRanks’ Stock Screener tool , we used the sector, analyst consensus rating and price target upside filters to scan the market for the crème-de-la-crème. As a result, we pinpointed 3 buy-rated healthcare names that have received substantial support from Wall Street analysts. One more thing – each boasts over 30% upside potential from current levels.
   Agios' IND for PKR Activator AG-946 Gets FDA Clearance  2020/03/24 12:08:00 Zacks Investment Research
The FDA passes Agios' (AGIO) investigational new drug application for its next-generation PKR activator, AG-946. The company plans to begin a phase I study on the same in mid-2020.
   The Daily Biotech Pulse: Pfizer's Eczema Drug Aces Latestage Study, Orphan Drug Designation For Dicerna, Dyadic's COVID-19 Connection  2020/03/19 11:37:15 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 18) Biomerica, Inc. (NASDAQ: BMRA )( announced commencement of international shipment of rapid COVID-19 test) BioNTech SE – ADR (NASDAQ: BNTX ) Imara Inc (NASDAQ: IMRA ) Down In The Dumps (Biotech Stocks Hitting 52-week lows on March 18) 89bio Inc (NASDAQ: ETNB ) AC Immune SA (NASDAQ: ACIU ) Acasti Pharma Inc (NASDAQ: ACST ) Accelerate Diagnostics Inc (NASDAQ: AXDX ) Aclaris Therapeutics Inc (NASDAQ: ACRS ) Adamas Pharmaceuticals Inc (NASDAQ: ADMS ) Adamis Pharmaceuticals Corp (NASDAQ: ADM ) Adial Pharmaceuticals Inc (NASDAQ: ADIL ) ADMA Biologics Inc (NASDAQ: ADMA ) Aerie Pharmaceuticals Inc (NASDAQ: AERI ) Aerpio Pharmaceuticals Inc (NASDAQ: ARPO ) AEterna Zentaris Inc. (NASDAQ: AEZS ) Agenus Inc (NASDAQ: AGEN ) Agios Pharmaceuticals Inc (NASDAQ: AGIO ) Aikido Pharma Inc (NASDAQ: AIKI ) Akorn, Inc. (NASDAQ: AKRX ) Alkermes Plc (NASDAQ: ALKS ) Allogene Therapeutics Inc (NASDAQ: ALLO ) Alterity Therapeutics Ltd (NASDAQ: ATHE ) AMAG Pharmaceuticals, Inc.
   Why Is Agios Pharmaceuticals (AGIO) Down 28.7% Since Last Earnings Report?  2020/03/14 15:30:46 Zacks Investment Research
Agios Pharmaceuticals (AGIO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
   Agios Pharmaceuticals (AGIO) Expected to Beat Earnings Estimates: Should You Buy?  2020/02/06 17:31:16 Zacks Investment Research
Agios Pharmaceuticals (AGIO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
   Analysts: 3 Healthcare Stocks That Could Gain 35% — Or More  2020/01/17 17:19:20 Nasdaq
Returns, that’s the name of the investing game. At the end of the day, investors are after the names that can help them generate a profit in the stock market. It’s as simple as that. The hard part, though, is determining which investment opportunities have the best chance of outperforming the market in the years to come. As not all stocks are created equal, Wall Street pros suggest doing some due diligence. This includes a close reading of what the analyst community has to say about the long-term growth prospects of a potential portfolio addition. Bearing this in mind, we applied this strategy to our own search for compelling investments in the healthcare space. With TipRanks’ Stock Screener tool , we used the sector, analyst consensus rating and price target upside filters to scan the market for the crème-de-la-crème. As a result, we pinpointed 3 buy-rated healthcare names that have received substantial support from Wall Street analysts. One more thing – each boasts over 30% upside potential from current levels.
   Agios' IND for PKR Activator AG-946 Gets FDA Clearance  2020/03/24 12:08:00 Zacks Investment Research
The FDA passes Agios' (AGIO) investigational new drug application for its next-generation PKR activator, AG-946. The company plans to begin a phase I study on the same in mid-2020.
   The Daily Biotech Pulse: Pfizer's Eczema Drug Aces Latestage Study, Orphan Drug Designation For Dicerna, Dyadic's COVID-19 Connection  2020/03/19 11:37:15 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 18) Biomerica, Inc. (NASDAQ: BMRA )( announced commencement of international shipment of rapid COVID-19 test) BioNTech SE – ADR (NASDAQ: BNTX ) Imara Inc (NASDAQ: IMRA ) Down In The Dumps (Biotech Stocks Hitting 52-week lows on March 18) 89bio Inc (NASDAQ: ETNB ) AC Immune SA (NASDAQ: ACIU ) Acasti Pharma Inc (NASDAQ: ACST ) Accelerate Diagnostics Inc (NASDAQ: AXDX ) Aclaris Therapeutics Inc (NASDAQ: ACRS ) Adamas Pharmaceuticals Inc (NASDAQ: ADMS ) Adamis Pharmaceuticals Corp (NASDAQ: ADM ) Adial Pharmaceuticals Inc (NASDAQ: ADIL ) ADMA Biologics Inc (NASDAQ: ADMA ) Aerie Pharmaceuticals Inc (NASDAQ: AERI ) Aerpio Pharmaceuticals Inc (NASDAQ: ARPO ) AEterna Zentaris Inc. (NASDAQ: AEZS ) Agenus Inc (NASDAQ: AGEN ) Agios Pharmaceuticals Inc (NASDAQ: AGIO ) Aikido Pharma Inc (NASDAQ: AIKI ) Akorn, Inc. (NASDAQ: AKRX ) Alkermes Plc (NASDAQ: ALKS ) Allogene Therapeutics Inc (NASDAQ: ALLO ) Alterity Therapeutics Ltd (NASDAQ: ATHE ) AMAG Pharmaceuticals, Inc.
   Why Is Agios Pharmaceuticals (AGIO) Down 28.7% Since Last Earnings Report?  2020/03/14 15:30:46 Zacks Investment Research
Agios Pharmaceuticals (AGIO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
   Agios Pharmaceuticals (AGIO) Expected to Beat Earnings Estimates: Should You Buy?  2020/02/06 17:31:16 Zacks Investment Research
Agios Pharmaceuticals (AGIO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
   Analysts: 3 Healthcare Stocks That Could Gain 35% — Or More  2020/01/17 17:19:20 Nasdaq
Returns, that’s the name of the investing game. At the end of the day, investors are after the names that can help them generate a profit in the stock market. It’s as simple as that. The hard part, though, is determining which investment opportunities have the best chance of outperforming the market in the years to come. As not all stocks are created equal, Wall Street pros suggest doing some due diligence. This includes a close reading of what the analyst community has to say about the long-term growth prospects of a potential portfolio addition. Bearing this in mind, we applied this strategy to our own search for compelling investments in the healthcare space. With TipRanks’ Stock Screener tool , we used the sector, analyst consensus rating and price target upside filters to scan the market for the crème-de-la-crème. As a result, we pinpointed 3 buy-rated healthcare names that have received substantial support from Wall Street analysts. One more thing – each boasts over 30% upside potential from current levels.

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 アギオス・ファ―マシュ―ティカルズ AGIO Agios Pharmaceuticals Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)